Associated Papers
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
Unraveling the unique amyloid-like aggregation behavior of the tumor suppressor p53 mutants in human cancers.
Manav N et al.
International Journal of Biological Macromolecules, 2025
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
Comprehensive classification of TP53 somatic missense variants based on their impact on p53 structural stability.
Tam B et al.
Briefings in Bioinformatics, 2024
Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma.
Khalil SS et al.
Cureus, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS et al.
Blood Advances, 2024
Molecular dynamics simulations suggest Thiosemicarbazones can bind p53 cancer mutant R175H.
Das T et al.
Biochimica Et Biophysica Acta. Proteins and Proteomics, 2023
Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.
Song H et al.
Science Translational Medicine, 2023
The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots.
Lazarian G et al.
Human Mutation, 2023
Insights into Allosteric Mechanisms of the Lung-Enriched p53 Mutants V157F and R158L.
Lei J et al.
International Journal of Molecular Sciences, 2022
Dissociation Pathways of the p53 DNA Binding Domain from DNA and Critical Roles of Key Residues Elucidated by dPaCS-MD/MSM.
Sobeh MM et al.
Journal of Chemical Information and Modeling, 2022
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR et al.
Chest, 2021
Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy.
Saleh A et al.
Cancers, 2021
The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction.
Vodicka P et al.
Cancers, 2021
Targeted-Gene Sequencing and Bioinformatics Analysis of Patients with Pancreatic Mucoepidermoid Carcinoma: A Case Report and Literature Review.
Chen Z et al.
Oncotargets and Therapy, 2021
Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.
Li H et al.
International Journal of Molecular Sciences, 2019
Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Evrard SM et al.
Haematologica, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket.
Pradhan MR et al.
Nucleic Acids Research, 2019
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).
Garziera M et al.
International Journal of Molecular Sciences, 2018
INDELseek: detection of complex insertions and deletions from next-generation sequencing data.
Au CH et al.
Bmc Genomics, 2017
Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer.
Tahara T et al.
Oncotarget, 2016
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
Fisher KE et al.
The Journal of Molecular Diagnostics : Jmd, 2016
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
Brannon AR et al.
Genome Biology, 2014
TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B et al.
Human Mutation, 2014
IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.
Stancheva G et al.
Biomed Research International, 2014
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Predicting the functional impact of protein mutations: application to cancer genomics.
Reva B et al.
Nucleic Acids Research, 2011
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.
Xu J et al.
Nature Chemical Biology, 2011